Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer.

PURPOSE To monitor cellular and metabolic characteristics of glioblastoma (GBM) over the course of standard 6-week chemoradiation treatment with chemical exchange saturation transfer (CEST)-MRI; and to identify the earliest time point CEST could determine subsequent therapeutic response. METHODS AND MATERIALS Nineteen patients with newly diagnosed GBM were recruited, and CEST-MRI was acquired immediately before (Day0), 2 weeks (Day14) and 4 weeks (Day28) into treatment, and 1 month after the end of treatment (Day70). Several CEST metrics, including magnetization transfer ratio and area under the curve of CEST peaks corresponding to nuclear Overhauser effect (NOE) and amide protons (MTRNOE, MTRAmide, CESTNOE, and CESTAmide respectively), magnetization transfer (MT), and direct water effect were investigated. Lack of early progression was determined as no increase in tumor size or worsening of clinical symptoms according to routine post-chemoradiation serial structural MRI. RESULTS Changes in MTRNOE (nonprogressors = 1.35 ± 0.18, progressors = 0.97 ± 0.22, P = .006) and MTRAmide (nonprogressors = 1.25 ± 0.17, progressors = 0.99 ± 0.10, P = .017) between baseline (Day0) and Day14 resulted in the best separation of nonprogressors from progressors. Moreover, the baseline (Day0) MTRNOE (nonprogressors = 6.5% ± 1.6%, progressors = 9.1% ± 2.1%, P = .015), MTRAmide (nonprogressors = 6.7% ± 1.7%, progressors = 8.9% ± 1.9%, P = .028), MT (nonprogressors = 3.8% ± 0.9%, progressors = 5.4% ± 1.4%, P = .019), and CESTNOE (nonprogressors = 4.1%ċHz ± 1.7%ċHz, progressors = 6.1%ċHz ± 1.9%ċHz, P = .044) were able to identify progressors even before the start of the treatment. CONCLUSIONS Chemical exchange saturation transfer (CEST) provides imaging-based biomarkers of GBM response as early as 2 weeks into the treatment. Certain CEST metrics can characterize tumor aggressiveness and identify early progressors even before beginning the treatment. Such an early biomarker of response may allow for adjusting the GBM treatment plan for adaptive radiation therapy in early progressors and more confidently continuing standard adjuvant treatment for nonprogressors.

[1]  Kimberly L Desmond,et al.  Understanding quantitative pulsed CEST in the presence of MT , 2012, Magnetic resonance in medicine.

[2]  O. Bieri,et al.  Imaging of Primary Brain Tumors and Metastases with Fast Quantitative 3‐Dimensional Magnetization Transfer , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[3]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ignacio Vallines,et al.  Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas , 2016, Oncotarget.

[5]  Hany Soliman,et al.  Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis , 2017, Magnetic resonance in medicine.

[6]  David C. Alsop,et al.  Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3Tesla , 2014, NeuroImage.

[7]  Edward Pan,et al.  In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma , 2014, Proceedings of the National Academy of Sciences.

[8]  H. Scherer.  Structural Development in Gliomas , 1938 .

[9]  Max A. Viergever,et al.  elastix: A Toolbox for Intensity-Based Medical Image Registration , 2010, IEEE Transactions on Medical Imaging.

[10]  Yue Cao,et al.  MR-guided radiation therapy: transformative technology and its role in the central nervous system. , 2017, Neuro-oncology.

[11]  Kimberly L Desmond,et al.  Mapping of amide, amine, and aliphatic peaks in the CEST spectra of murine xenografts at 7 T , 2014, Magnetic resonance in medicine.

[12]  Bruce R. Rosen,et al.  Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival , 2017, npj Precision Oncology.

[13]  Erik Tryggestad,et al.  Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides , 2010, Nature Medicine.

[14]  Benjamin Schmitt,et al.  Relaxation-compensated CEST-MRI of the human brain at 7T: Unbiased insight into NOE and amide signal changes in human glioblastoma , 2015, NeuroImage.

[15]  Diana Delgado,et al.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis , 2017, Neuro-oncology.

[16]  Hye-Young Heo,et al.  Applying amide proton transfer‐weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas , 2016, Journal of magnetic resonance imaging : JMRI.

[17]  Xavier Golay,et al.  Amide proton transfer imaging of human brain tumors at 3T , 2006, Magnetic resonance in medicine.

[18]  R. Bartha,et al.  Imaging chemical exchange saturation transfer (CEST) effects following tumor‐selective acidification using lonidamine , 2015, NMR in biomedicine.

[19]  Pieter Wesseling,et al.  Diffuse glioma growth: a guerilla war , 2007, Acta Neuropathologica.

[20]  R. Gonzalez,et al.  MRI in treatment of adult gliomas. , 2005, The Lancet. Oncology.

[21]  Bennett A Landman,et al.  Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments , 2009, Magnetic resonance in medicine.

[22]  J. King,et al.  Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries , 2012, Cancer.

[23]  J. M. Pauly,et al.  Drift in the magnetization transfer signal : effect on quantitative MT experiments , 2010 .

[24]  G. Stanisz,et al.  A novel method for simultaneous 3D B1 and T1 mapping: the method of slopes (MoS) , 2012, NMR in biomedicine.

[25]  Jinyuan Zhou,et al.  Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI , 2003, Nature Medicine.

[26]  G. Stanisz,et al.  Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy , 2018, Scientific Reports.

[27]  R. Weichselbaum,et al.  Improved survival time trends for glioblastoma using the SEER 17 population-based registries , 2012, Journal of Neuro-Oncology.

[28]  Hany Soliman,et al.  Differentiation between Radiation Necrosis and Tumor Progression Using Chemical Exchange Saturation Transfer , 2017, Clinical Cancer Research.

[29]  A. Waldman,et al.  Quantitative magnetisation transfer imaging in glioma: preliminary results , 2011, NMR in biomedicine.

[30]  F. Hyder,et al.  Temozolomide arrests glioma growth and normalizes intratumoral extracellular pH , 2017, Scientific Reports.

[31]  Hui Zhang,et al.  The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis , 2016, European Radiology.

[32]  P. LaViolette,et al.  Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. , 2014, Neuro-oncology.